BD - Earth day 2024

Abzena Introduces LabZient™ for Faster Antibody IND Approval

Thursday, February 08, 2024

Abzena, a prominent integrated CDMO specializing in complex biologics and bioconjugates, has unveiled its latest analytical platform, LabZient™. This innovative platform offers a standardized and automated approach to evaluating and validating large molecules, resulting in significant reductions in both drug development timelines and resource costs.

LabZient™ utilizes a combination of predictive in-silico evaluation and established laboratory methods, minimizing the need for extensive method qualification testing. By leveraging their analytical expertise and development data, LabZient™ provides early insights into critical antibody quality attributes (CQA), enabling informed decisions and enhancing downstream clinical and commercial success.

LabZient™ was developed in response to customer feedback and industry demand for operational efficiencies, especially among pharma and biotech companies facing tight timelines and limited financing. By delivering high-quality data in a faster manner, the platform helps expedite the path to IND and streamlines analytical testing across portfolios sharing a common modality.

Initial assessments suggest that LabZient™ methods are applicable to a broad range of antibodies, including monoclonal antibodies (mAbs), antibody fragments (Fabs), and bispecifics, with plans to extend its capabilities to Antibody-drug conjugates (ADCs) in the near future.


Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit